Sanofi appoints chairman of SDSAC

Dr Gary Nabel succeeds Dr Richard Klausner

Gary Nabel has become chairman of Sanofi’s Strategic Development and Scientific Advisory Council (SDSAC).

Dr Nabel, currently senior vice president, chief scientific officer and deputy to Elias Zerhouni, president, Global R&D, will succeed Richard Klausner. He will direct the activities of the Council, including selection, appointment and evaluation of advisers.

Created in November 2010, the Council aims to enhance scientific discovery in a collaborative approach and to develop a world-class research and development platform for future innovation. The Council’s role is to advise Sanofi on new and emerging areas of science and technology as well to create a strong network of scientists and institutional partnerships.

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)
Research & Development

Sanofi's tolebrutinib meets primary endpoints in Phase III HERCULES MS trial

The therapeutic has the ability to delay the onset of confirmed disability progression in patients, which is significant area of unmet need in the MS patient population
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Research & Development

C4XD receives first milestone payment of €3 million from Sanofi

€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Subscribe now